Professional Documents
Culture Documents
SasiwimonTalummuk, Pavinee Sriboonruang and Metta Makhanon Novartis (Thailand) Ltd., Bangkok, Thailand Sasiwimon.Talummuk@Novartis.com, Pavinee.Sriboonruang@Novartis.com and Metta.Makhanon@Novartis.com
Introduction
Mycoplasma hyopeumoniae (M. hyo) is the etiology pathogens of enzootic pneumonia (EP) and primary cause of Porcine Respiratory Disease Complex (PRDC)1. Good practice management, vaccination and medication are general strategies for controlling and preventing of productivity losses from the disease. The aim of this study was to determine the efficacy of a single dose aqueous inactivated M. hyo vaccine (PneumoSTAR Myco) in water in oil in water adjuvant (ImmuneSTAR) and to compare with conventional M. hyo vaccine used on a farm.
grading of both groups were performed at slaughter house. The mean lung lesion score result was statistically analyzed by ANOVA test at p<0.05.
Results
There were significant differences in mean lung lesions of pigs vaccinated with PneumoSTAR Myco and conventional M. hyo vaccine. The percentage of lung lesion score was shown in Figure 1. There were no differences in the pleurisy between both groups. However, percentage of pleurisy in pigs vaccinated with conventional M. hyo vaccine was
30 20 10 0
0
LS = Lung Lesion
LS5
5<LS10
LS 10
60 40 20 0
No Grade 1 Grade 2
References
1. Thacker, E.L. et al., 1998. Swine Heath and Production,6,3,107-112. 2. Groth, D. et al., 2001. Proce. of the Swine Conference,41 3. Thacker, E.L., 2006. Disease of Swine. Iowa State University Press, Ames, PP.701-717. 4. Maes, D., 2010. Proce. of IPVS 21Th Congress, 30-35.
Denagard is a registered trademark of Novartis AG, Basel, Switzerland. 2011 Novartis Animal Health Inc.